55745-96-5

Usage

Uses

Used in Pharmaceutical Industry:
6-Benzofurancarboxaldehyde, 2,3-dihydro(9CI) serves as an essential intermediate in the synthesis of various pharmaceuticals. Its unique chemical structure contributes to the development of new drugs with potential therapeutic applications.
Used in Fragrance Industry:
Leveraging its strong and distinct odor, 6-Benzofurancarboxaldehyde, 2,3-dihydro(9CI) is used as a fragrance ingredient in the production of perfumes, colognes, and other scented consumer products, enhancing their olfactory profiles.
Used in Organic Synthesis:
Beyond its applications in pharmaceuticals and fragrances, 6-Benzofurancarboxaldehyde, 2,3-dihydro(9CI) is utilized in the synthesis of other organic compounds, highlighting its versatility in organic chemistry.
Used in Antimicrobial and Antifungal Applications:
Research into the potential medicinal properties of 6-Benzofurancarboxaldehyde, 2,3-dihydro(9CI) has revealed its antimicrobial and antifungal activities, suggesting its use in applications requiring the inhibition of microbial growth, such as in preservatives or disinfectants.

Upstream product

• 68-12-2 N,N-dimethyl-formamide 
• 189035-22-1 6-bromo-2,3-dihydro-1-benzofuran 
• 377091-18-4 1,4-dibromo-2-(2-bromoethoxy)benzene 
• 377091-17-3 1,4-dibromo-2-hydroxyethoxybenzene 
• 1435-52-5 2,5-dibromofluorobenzene 

Downstream Products

• 1430416-91-3 C₂₂H₂₂O₇ 
• 1430416-99-1 C₂₂H₂₃NO₇ 
• 1430417-21-2 (E)-1-(allyloxy)-3-(3,4-dimethoxyphenyl)-1-oxopropan-2-yl 3-(2,3-dihydrobenzofuran-6-yl)acrylate 
• 55746-20-8 (2,3-dihydrobenzofuran-6-yl)methanamine 

Relevant academic research and scientific papers

SPIRO COMPOUNDS AS GLYCOSIDASE INHIBITORS

Compounds of formula (I) wherein A, R, L, Z, Q1, Q2 and n have the meaning according to the claims can be employed, inter alia, for the treatment of tauopathies and Alzheimer's disease.

TETRAHYDRO-BENZOAZEPINE GLYCOSIDASE INHIBITORS

Compounds of formula (I') wherein A, R1, R2, T1, T2, T3, T4, L, W, Z, R''', m and n have the meaning according to the claims can be employed, inter alia, for the treatment of tauopathies and Alzheimer's disease.

FUSED GLYCOSIDASE INHIBITORS

Compounds of formula (I), wherein A, Z, E, R1, R2, m and n have the meaning according to the claims can be employed, inter alia, for the treatment of tauopathies and Alzheimer's disease.

Methods for treating neisseria gonorrhoeae infection with substituted 1,2-dihydro-2A,5,8A-triazaacenaphthylene-3,8-diones

The present invention relates to methods for treating Neisseria Gonorrhoeae infection which comprises administering to a subject in need thereof novel 1,2-dihydro-2a,5,8a-triazaacenaphthylene-3,8-dione compounds: or pharmaceutically acceptable salts thereof and/or corresponding pharmaceutical compositions.

ANNULATED GLYCOSIDASE INHIBITORS

Compounds of formula (I) wherein A, R, W1, W2, W3, W4, W5, W6, L, Q, Rx and u have the meaning according to the claims can be employed, inter alia, for the treatment of tauopathies and Alzheimer's disease.

LINEAR GLYCOSIDASE INHIBITORS

Compounds of formula (I) wherein A, R, W, Q, L, n and m have the meaning according to the claims can be employed, inter alia, for the treatment of tauopathies and Alzheimer's disease.

OGA INHIBITOR COMPOUNDS

The present invention relates to O-GlcNAc hydrolase (OGA) inhibitors. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which inhibition of OGA is beneficial, such as tauopathies, in particular Alzheimer's disease or progressive supranuclear palsy; and neurodegenerative diseases accompanied by a tau pathology, in particular amyotrophic lateral sclerosis or frontotemporal lobe dementia caused by C90RF72 mutations.

GLYCOSIDASE INHIBITORS

Compounds of formula (I) wherein A, R, W, Q, n and m have the meaning according to the claims can be employed, inter alia, for the treatment of tauopathies and Alzheimer's disease.

GLYCOSIDASE INHIBITORS

Compounds of formula (I) wherein A, R, W, Q, n and m have the meaning according to the claims can be employed, inter alia, for the treatment of tauopathies and Alzheimer's disease.

PROCESS FOR THE SEPARATION OF ENANTIOMERS OF PIPERAZINE DERIVATIVES

The invention relates to a process for preparing either enantiomer of a compound of formula (I), wherein X, Y and n have the meaning given in claim 1, with high enantiomeric excess (e.e.), by chiral resolution in the presence of a non-racemic, chiral acid.